Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. The standard therapy for DLBCL is R-CHOP. The current 5-year overall survival is 60%
Approximately 50% of all DLBCL patients are aged between 60 and 85 years. 6 Many patients in this age group have several comorbidities. Preexiting cardiac disease may prevent the use of doxorubicin, which has an integral impact on the efficacy of R-CHOP therapy. 7 Age over 65 years is also a significant risk factor for anthracyclineinduced cardiotoxicity, 8 and therefore, the use of R-CHOP is often withheld from elderly patients. 7 There is no standard therapy protocol for this group of patients. 9, 10 A common way to solve this problem has been to treat these patients with alternative regimens such as R-CVP, R-mini-CHOP, or R-bendamustine, which have all shown unsatisfactory results in DLBCL. 11, 12 Etoposide (VP-16) is an active agent in lymphomas, and the efficiency of etoposide was investigated in the prerituximab era in particular. 13 Epirubicin is an anthracycline that is less cardiotoxic compared with doxorubicin. 14 
| Matched-pair analysis
Matched-pair analysis was carried out between R-CHOP and R-CEOP.
Patients were matched based on IPI and age (within 6 years). Two patients treated with R-CEOP were excluded from analysis because a pair was not found.
PFS was calculated in this analysis from the day of diagnosis to date of progression, date of relapse, date of last status for patients who died due to treatment, or last follow-up date.
3 | RESULTS
| Patients
Patient demographics are presented in Table 1 In the R-CHOP group, 15 out of 55 patients presented with a non-GC phenotype, in the R-CIOP group 30 out of 105, and in the R-CEOP group 10 out of 17 (p = 0.074).
| Treatment outcome
The PFS and OS are presented in Figure 1 by treatment group. When studying all patients over 70 years of age (n = 88), the 2-year DSS was 80.2%. In the group of patients over 70 who were treated with R-CHOP, it was 91.7%, with R-CIOP 65.5%, and with R-CEOP, it was 92.9%. Among patients treated with R-CEOP, one received only one cycle of treatment, two patients received four cycles, two received five cycles, 10 received six cycles, and two received eight cycles of treatment.
| Toxicity
From all patients, 3.4% (n = 7) died due to treatment-related complications. There were five fatal neutropenic infections, one pulmonary reaction, and one allergic reaction to contrast agent. All of these seven patients were treated with R-CIOP. The mean age was 73.0 years at the time of diagnosis in this patient group.
| Matched-pair analysis
The demographics of the matched-pair analysis are presented in Table 2 . The PFS and DSS are presented in Figure 2 The asterisk indicates if the difference was statistically significant (P < 0.05) between the treatment groups.
The R-CHOP regimen is the standard of care in DLBCL giving a 5-year OS rate of 60% to 70%. 2 However, DLBCL is common in elderly patients and there is no standard therapy for this patient group. Tolerance of standard therapy is often impaired, and the presence of comorbidities, altered drug metabolism, and diminished organ function may cause severe complications. 16 Treatment-related mortality is also higher, up to 8.7% in elderly patients. 17 Cardiac diseases are common in elderly patients. Doxorubicin is an anthracycline chemotherapeutics, an essential agent in the R-CHOP regimen, and its major problem is cardiotoxicity. In 3164 lymphoma patients treated with doxorubicin, 28% developed a subclinical cardiomyopathy during next 5 years following the initial treatment. 18 High age, higher cumulative doses, preexisting heart disease, hypertension, diabetes, comorbidities, 7 and chest radiation therapy 19 increase the risk of doxorubicin-related congestive heart failure. There is a wide individual variability in cardiotoxic anthracycline doses, and particularly, in patients with risk factors, cardiotoxicity may also occur at a low cumulative dose. 20 Many other approaches have been used to treat these patients.
When treating with dose-reduced R-CHOP, 21 or so called R- Epirubicin has been regarded as a less cardiotoxic anthracycline than doxorubicin. One study of 88 patients treated with R-CIOP has been published previously. From these patients, 63.6% were 60 or younger, and 5-year OS of 70.5% was observed. 26 In Oulu University
Hospital, epirubicin has been used in elderly patients in R-CIOP regimen in order to reduce cardiotoxicity. In the patients treated with R-CIOP in the present series, the 2-year PFS was 64.4% and the 2-year DSS was 72.1%. The mean age of the patients was 70.5 years. Thus, R-CIOP seems to be an inferior regimen compared with R-CEOP or R-CHOP.
Etoposide is a derivative of podophyllotoxin, which blocks cells in the premeiotic stage of the cell cycle. 27 The results of etoposide only and etoposide combined with different chemotherapy regimens were investigated in the prerituximab era in particular. 13 There are limited data available on the use of R-CEOP in DLBCL. In a series of 81 patients treated with R-CEOP with a median follow-up of 28 months, the 5-year time to progression rate was 57% with R-CEOP and no statistically significant difference was found when compared with R-CHOP treated patients (p = 0.21), suggesting that R-CEOP could be a curative, alternative treatment for patients not eligible for R-CHOP.
The 5-year OS was 49% in the R-CEOP group and 64% in the R-CHOP group, reflecting the high number of comorbidities in R-CEOP group. 28 Another study of 26 patients treated with R-CEOP has been published. With a median follow-up time of 19 months, the 2-year PFS and OS rates were 49% and 59%. 29 In our analysis of 17 elderly patients with impaired cardiac function, a 2-year PFS of 87.7% and OS of 69.0% were achieved with R-CEOP. The toxicity rate related to the R-CEOP regimen seems to be low according to our data.
No treatment-related deaths occurred.
Because the patients treated with R-CEOP were older than those This is a retrospective study with all the limitations associated with retrospective setting. Although the total number of patients, 208, is considerable, the number of patients in the R-CEOP group was limited. However, the matched-pair analysis with R-CHOPtreated patients improves the reliability of this study. We have reported the treatment related mortality, but the retrospective design hindered the detailed comparison of nonfatal toxicity between the groups. These results should be verified with a larger patient group and in prospective studies. However, because these elderly patients with cardiac comorbidities are usually excluded from clinical trials, we find that our study adds information to treatment selection in this patient group and implies that even these old fragile patients can be treated with curative intent.
| CONCLUSIONS
In this retrospective analysis, we found that R-CEOP offers favourable results and good disease control in the treatment of elderly patients with DLBCL and the result seems to be comparable with R-CHOP. In line with existing literature, it seems that doxorubicin can safely be substituted with etoposide in patients with preexisting cardiac disease.
However, the results with R-CIOP were unsatisfactory and we do not recommend using this protocol in elderly patients with cardiac disease.
